Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate
70-80% of women with PCOS (PMOS) face insulin resistance
Clinical trials show this clearly
Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes
Were diving into the important facts about vitamin B12 dosage and its effect on nerve pain and peripheral neuropathy
Whats inside the box